ROCKVILLE, MARYLAND, March 24, 2016 – At its first Demo Day on March 23, Relevant Health, a health technology startup accelerator in the Washington, DC metro area, hosted a group of more than 150 investors, industry leaders and top technology company representatives to experience first-hand the progress of the accelerator’s seven health tech startups. Coming from Bethesda, Rockville, Washington, DC, Baltimore, New York City and Latvia, the startups are developing a wide range of health tech products and devices to meet the healthcare needs of a diverse patient population. The new accelerator is supported by BioHealth Innovation (BHI), ProductSavvy and Montgomery County Economic Development.
“Our first graduating cohort from the first health tech accelerator in Montgomery County is a great success,” stated Rich Bendis, BHI President and CEO. “The BHI-developed nationally competitive acceleration program has attracted seven high-quality startups that have dedicated the last five months to the Relevant Health program. We are very proud of their accomplishments. Additionally, we are very pleased with the caliber of investors that have taken a significant interest in Relevant Health.”
Our mission: improve newborn survival and health in the developing world
We are developing cutting edge healthcare technologies for where they’re gravely needed and will have an incredible impact—vulnerable populations in low-resource countries. Annually, over 46 million newborns in developing countries around the world need interventions for complications that happen at or around birth, 600,000 in Uganda alone. Every Neopenda device has the potential to save the life of a newborn for less than $1, once it is produced at scale.
Join us on March 30th for an evening of networking around innovation and commercialization at the BioBuzz @ Relevant Health. Meet with the organizations fueling commercialization in Maryland – BHI & TEDCO – and mingle with the first cohort of companies in the regions newest BioHealth accelerator – Relevant Health.
The Montgomery County Economic Development Corporation (MCEDC) was officially designated as the County’s Economic Development Organization by the County Council, marking a big and bold step toward achieving greater economic competitiveness and prosperity in Montgomery County. As the County’s new lead economic development organization, MCEDC is replacing both the County Department of Economic Development (DED) and the Montgomery Business Development Corporation (MBDC) effective July 1, 2016, as the primary point of contact for the local, regional, national and international business community.
Intralytix, Inc., announced today that the company has received a SBIR Phase II grant from the U.S. Department of Agriculture (USDA), National Institute of Food and Agriculture (NIFA), to develop a bacteriophage (or phage) cocktail effective against the larval shellfish pathogens Vibrio tubiashii and Vibrio coralliilyticus. This research will be a continuation of collaborative efforts between Intralytix and Dr. Gary Richards, the Lead Scientist at the USDA, Agricultural Research Service (ARS) laboratory in Dover, Delaware, where these phages were originally isolated and characterized. A spokesperson for the company noted that, in developing this proposed technology, Intralytix will be working closely with Dr. Chris Langdon at the Hatfield Marine Station, Oregon State University, in Newport, Oregon, and Dr. Claudia Hӓse at the College of Veterinary Medicine, Oregon State University, in Corvallis, Oregon. In addition, the company will receive continuing research support from Dr. Richards’ group at the ARS USDA.
Roche Holding AG, the world’s largest producer of cancer drugs, is opening the door to more external partnerships as its latest and most promising tumor-fighting treatment heads for approval this year.
The Maryland Technology Development Corporation (TEDCO) announced today that 17 companies have received over $1.7 million in funding from the organization’s Technology Commercialization Fund (TCF) and Cyber Security Investment Fund (CIF)in the last six months. The funding will be used to advance the companies’ technology and product commercialization efforts.
DATE: Wednesday, April 13, 2016 (FINAL EVENT) TIME: 3:30-5:00PM
LOCATION: Montgomery County Department of Economic Development, 111 Rockville Pike, Suite 800, Rockville, MD 20850
We would like to offer one of our best and brightest as our final speaker for the Tech Transfer Speakers Series. Launching one successful company is challenging, but founding six or more is an art. Plan to attend our final program on April 13 with one of our area’s prolific entrepreneurs. Specific points of interest and discussion will include: fundraising, launching the idea, identifying a technology that will sell, working with tech transfer officers to license the technology, and the future of innovation investment in the United States, Asia and Europe. Bring your best questions. This will be an exciting conversation!
For the last several years, Martine Rothblatt has been positioning United Therapeutics to manufacture transplantable human organs. This week, the founder and CEO of the Maryland biotech cornerstone told the state’s tech community to get ready for a new industry to sprout from the idea.
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) announced today that additional data supporting the Company’s novel, investigational anti-cancer therapeutic, Supinoxin™ (RX-5902), for the treatment of triple negative breast cancer, were presented at the 14th Annual Targeted Anticancer Therapeutics Congress (TAT 2016), held in Washington, DC March 21- 23, 2016.
SPIRIT OF INNOVATION: “We spend a lot of effort in recruitment to find the right culture fit,” says Gorkem Sevinc, CTO of emocha Mobile Health. What’s more, the solutions developed by Sevinc and his team help patients with medication and care plan adherence, a task that can literally save lives. “This drives our team to go above and beyond,” he says.
Maryland universities have ramped up efforts in recent years to help students and faculty turn their discoveries into growing businesses but lag far behind many colleges around the country in spinning off companies and pulling in millions of dollars in licensing revenue.
A Baltimore health startup is among the new class of companies entering Dreamit’s accelerator program.
Timonium-based Kermit was developed by a team that consulted for hospitals on the purchase of implantable medical devices for knees, hips and other body parts.
An investment firm targeting seed stage investment in health IT and other software startups is raising a $50 million fund, according to a report by Fortune.
Two of the investors behind Refactor Capital’s fund have worked for Google: David Lee, who also co-founded SV Angel and Zal Bilimoria, who has worked for Andreessen Horowitz.
The Division of Industrial Innovation and Partnerships (IIP), within the Directorate for Engineering at the National Science Foundation, announces a nationwide search to fill multiple Program Director positions for the Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) program.
Formal consideration of interested applications will continue until these positions are filled.
Attempting to free people with diabetes from frequent finger-pricks and drug injections, researchers have created an electronic skin patch that senses excess glucose in sweat and automatically administers drugs by heating up microneedles that penetrate the skin.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
